This program is supported through an independent educational grant from Novo Nordisk. It is intended exclusively for healthcare professionals in the United States.

In this 45-minute live virtual roundtable, U.S.-based sickle cell disease (SCD) experts Enrico Novelli, MD; Donnell Ivy, MD; and Biree Andemariam, MD—moderated by Chair Nirmish Shah, MD—discuss practical, evidence-based strategies to improve outcomes for adults living with SCD.

Through real-time dialogue and patient-centered insights, the panel will explore how to detect and manage long-term organ dysfunction, integrate emerging and multimodal therapies, and apply patient-reported outcomes (PROs) to personalize care planning.

Accreditation: 0.75 AMA PRA Category 1 Credit™ will be available for this activity

This expert-led discussion will equip healthcare professionals with the tools needed to deliver more coordinated, individualized, and effective care in 2025 and beyond.

Session Highlights

• Detect early and act fast: Apply screening and management strategies for cardiopulmonary, renal, and neurologic complications in adult SCD.
• Translate trials into treatment: Confidently implement emerging therapies and multimodal approaches, including opioid-sparing pain strategies and gene-based interventions.
• Center care on what matters: Use validated PROs and quality-of-life measures to inform shared decision-making and optimize outcomes.

Who Should Watch

• Hematologists
• Primary care physicians
• Emergency medicine physicians
• Pulmonologists
• Cardiologists
• Nephrologists
• Nurse practitioners
• Physician assistants
• Pharmacists
• Other HCP involved in SCD management

Presented by

Chair:

Dr. Nirmish Shah, MD - is Director of the Sickle Cell Transition Program at Duke University, where he specializes in the care of children and adults with sickle cell disease. His clinical approach emphasizes education, empowerment, and comprehensive support, medical, psychological, and social, to help patients navigate the challenges of living with a chronic condition. Dr. Shah’s research focuses on leveraging mobile health technology to improve patient engagement, with a particular emphasis on helping children better manage symptoms and medication adherence. Outside of medicine, he has a background in biological illustration and enjoys drawing plants, animals, and people in his spare time.

Speaker:

Dr. Enrico Novelli, MD, MS - is Associate Professor of Medicine and Division Chief of Classical Hematology at the University of Pittsburgh, where he also serves as Director of the UPMC Adult Sickle Cell Disease Program and Section Chief of Benign Hematology. Trained in medicine at the University of Milan and in postdoctoral research at Johns Hopkins University, Dr. Novelli has built a career at the intersection of translational science and global health. His research focuses on vascular dysfunction in sickle cell disease (SCD), including the roles of thrombospondin-1, arterial stiffness, and cerebral small vessel disease. His work has identified clinical biomarkers and mechanisms that may help stratify risk and guide treatment in SCD.

Dr. Donnell Ivy, MD - serves as Chief Medical Officer for the Sickle Cell Disease Association of America (SCDAA), Education Manager at the Sickle Cell Awareness Group of Ontario (SCAGO), and Registry & Mentorship Manager at GANSID. Previously, Dr. Ivy was Program Director for the Hemoglobinopathies Program at the Maternal and Child Health Bureau of HRSA, overseeing national initiatives such as the Sickle Cell Disease Treatment Demonstration Program, the Newborn Screening Program, and the Thalassemia Program. His work bridges clinical experience and public health strategy to strengthen care infrastructure and patient outcomes.

Dr. Biree Andemariam, MD - Professor of Medicine at the University of Connecticut School of Medicine, Founding Director of the New England Sickle Cell Institute, and Director of the Connecticut Bleeding Disorders Center. A nationally recognized expert in sickle cell disease, she leads clinical and translational research focused on improving outcomes and advancing emerging therapies. A former Chief Medical Officer and current Board Member of the Sickle Cell Disease Association of America, Dr. Andemariam champions innovation in SCD care.

With Advocacy from the Sickle Cell Disease Association of America (SCDAA)

Continuing Education Information

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Dr Edward Donnell Ivy has disclosed financial relationships within the past 24 months with the following ineligible companies. He has served as a paid consultant for Novo Nordisk and Pfizer, and as a staff member (Education Coordinator) for the Sickle Cell Awareness Group of Ontario.

Dr Nirmish Shah has disclosed financial relationships within the past 24 months with the following ineligible companies. He has received consulting fees from Bluebird Bio, Agios, Vertex, and Novo Nordisk. He has received consulting fees, research support, and speaker honoraria from Pfizer, and speaker honoraria from Emmaus Pharmaceuticals.

Dr Enrico Novelli has disclosed financial relationships within the past 24 months with the following ineligible companies. He has served as a consultant and advisory board member for Novo Nordisk, Novartis, Shield Therapeutics, and Chiesi Pharmaceuticals.

Dr Biree Andemariam has disclosed financial relationships within the past 24 months with the following ineligible companies. She has received consulting fees and research funding from Afimmune, Agios, Hemanext, Novartis, Novo Nordisk, and Pfizer. She has served as a consultant for Bluebird Bio, Octapharma, Roche, Sanofi, Vertex, Editas, Fulcrum, and Beam Therapeutics.

These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Speakers do not intend to discuss non-FDA uses of drug products and/or devices and their unlabelled indications, and will disclose this to the audience when such discussion takes place.

AffinityCE staff, MedAll staff, and all planners and reviewers have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.

Activity Accreditation for Health Professions

Physicians

This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE will designate this live activity a maximum of 0.75 AMA PRA Category 1 Credits™.

Physician Assistants

This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE will designate this live activity a maximum of 0.75 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE will designate this live activity a maximum of 0.75 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

How to Earn Your CME Credit:

To receive your CME certificate, attend the full webinar and complete the post-session assessment. A link to your certificate will be provided automatically upon completion.

Participation Costs

There is no cost to participate in this program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and

2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

This activity will start on October 30th 2025 and end on October 30th 2026. estimated time to complete: 45 minutes